Shilpa Medicare Ltd

Shilpa Medicare Secures European Approval for Rotigotine Patch 🚀

- Shilpa Medicare received initial European authorization for its Rotigotine transdermal patch (1, 2, 3, 4, 6, 8 mg/24h).

- Generic version of Neupro®, treating Restless Legs Syndrome and Parkinson’s disease.

- Total European market potential: ~$222 million.

- First transdermal patch approval for Shilpa in Europe.

- Manufactured at Unit VI, Dobbaspet, Bengaluru—facility’s first EU-approved prescription transdermal product.

- Facility specializes in oral dispersible films and transdermal patches.

- Strategic commercialization partner secured for FY27 launch.